Janssen begins Phase I trial of its Ebola vaccine
US healthcare giant Johnson & Johnson’s (NYSE: JNJ) Europe-based subsidiary Janssen has begun a first-in-human Phase I trial of an Ebola vaccine.
The trial, being led by the Oxford Vaccine Group at the University of Oxford Department of Pediatrics, UK, is currently recruiting patients, with the first volunteers already receiving their initial vaccine dose. Enrolment is expected to be complete by the end of January.
It will evaluate the safety and tolerability of a prime-boost vaccine regimen, where patients will first be given a dose to prime the immune system, then a boost intended to enhance the immune response over time. The trial will look at the reaction of 72 healthy adult volunteers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze